Biotechnology

Exeliom Biosciences Announces First Patient Enrolled in Phase 1 Study for the Maintenance in Remission in Adult Patients With Mild to Moderate Crohn's Disease

March 21, 2023 7:50 AM

PARIS & DIJON, FRANCE / ACCESSWIRE / March 21, 2023 / Exeliom Biosciences, a biotechnology company, announced today the enrollment of the first patient in its Phase 1 clinical study of an investigational oral single-strain microbiome therapeutic (EXL-01) developed to prolong the maintenance in remission in adult patients with mild to moderate forms of Crohn's disease. EXL01 is a once-daily, potentially first-in-class, microbiome-based...

Read more

GB Sciences' First International Patent Protecting Its Proprietary Cannabinoid-Based Formulations for Parkinson's Disease Has Been Issued in China

March 20, 2023 7:00 AM

According to Statista, China has the second largest pharmaceutical market in the world and plant-based medicines are very well accepted, which makes China a potential target market for Gb Sciences. LAS VEGAS, NV / ACCESSWIRE / March 20, 2023 / Gb Sciences, Inc. (OTCQB:GBLX), a leading cannabis- and plant-inspired biopharmaceutical research and development company, has recently been issued a patent in China to protect its proprietary...

Read more

Plandai Biotechnology, Inc. Announces Entry into Material Share Exchange Agreement with Good Salt, LLC

March 20, 2023 7:00 AM

SAN DIEGO, CA / ACCESSWIRE / March 20, 2023 / Plandai Biotechnology, Inc. (OTC PINK:PLPL) announces it has entered into a binding memorandum of understanding to close a share exchange agreement with Good Salt, LLC, a Florida limited liability company. Good Salt is the successor in interest to material tangible and intangible assets, cash and cash equivalents, inventory, and the active operations of two Florida limited liability companies,...

Read more

Scailyte Announces Collaboration With Turnstone Biologics to Identify Biomarker Signatures in Solid Tumors With TIL Therapy

March 17, 2023 4:00 PM

BASEL, SWITZERLAND / ACCESSWIRE / March 17, 2023 / Scailyte AG, an ETH Zürich spin-off with a proprietary analytical sequencing, and data analysis platform to draw insights into complex disease patterns from single-cell data, today announced that it entered into a collaboration with Turnstone Biologics to discover signature biomarkers predictive of clinical responses to tumor-infiltrating lymphocyte (TIL) therapy by applying ScaiVision®,...

Read more

Biophytis Announces Ratio Change Under its American Depositary Receipt (“ADR”) Program

March 17, 2023 3:20 AM

PARIS, FRANCE / CAMBRIDGE, MA / ACCESSWIRE / March 17, 2023 / Biophytis SA (NasdaqCM:BPTS, Euronext Growth Paris:ALBPS) (the "Company" or "Biophytis"), a clinical-stage biotechnology company focused on the development of therapeutics that slow the degenerative processes associated with aging, including severe respiratory failure in patients suffering from COVID-19, today annouces that it will change the ratio of its American Depositary Shares...

Read more

Edesa Biotech to Present Favorable Dermatitis Drug Results at American Academy of Dermatology Association Annual Meeting

March 16, 2023 4:10 PM

TORONTO, ON / ACCESSWIRE / March 16, 2023 / Edesa Biotech, Inc. announced today that the company has been selected to present clinical trial data from a Phase 2B multi-dose study of its EB01 drug candidate at a Late Breaking Abstract session of the American Academy of Dermatology Association (AAD) annual meeting being held March 17-21, 2023. The presentation will detail the statistically significant topline results achieved by 1.0% EB01 cream in...

Read more

Dermata Therapeutics Announces Pricing of $5.0 Million Public Offering

March 16, 2023 1:15 PM

SAN DIEGO, CA / ACCESSWIRE / March 16, 2023 / Dermata Therapeutics, Inc. ("Dermata," or the "Company") (Nasdaq:DRMA; DRMAW), a clinical-stage biotechnology company focusing on the treatment of medical and aesthetic skin conditions, today announced the pricing of a public offering of 1,618,123 shares of the Company's common stock (or pre-funded warrants in lieu thereof) and accompanying Series A warrants to purchase up to 1,618,123 shares of...

Read more

De Novo Dairy Announces Rebrand and Headquarters Move to London

March 16, 2023 1:00 PM

De Novo Dairy, a leading precision fermentation company, announced today its official rebrand to De Novo Foodlabs. The new name reflects the company's expanded focus on creating sustainable nutrients that improve the health of people and the planet through precision fermentation and other technologies. LONDON, ENGLAND / ACCESSWIRE / March 16, 2023 / De Novo Dairy, a leading precision fermentation company, announced today its official rebrand to...

Read more

Nulixir Earns NSF's Good Manufacturing Practice Registration

March 16, 2023 9:00 AM

Independent registration from the global public health organization demonstrates a commitment to dietary supplement quality and compliance with U.S. GMP requirements AUSTIN, TX / ACCESSWIRE / March 16, 2023 / Nulixir Inc. manufacturing facility in Austin, Texas, was recently added to NSF International's dietary supplements Good Manufacturing Practice (GMP) registration. Earning GMP registration from NSF verifies that a manufacturing facility has...

Read more

Xenetic Biosciences, Inc. to Present at the Virtual Investor NETs in Cancer Spotlight Event

March 16, 2023 8:05 AM

Live video webcast with moderated roundtable with members of the Xenetic leadership team and recognized oncology leader and NETs researcher, Jonathan Spicer, MD, PhD on Wednesday, March 29th at 11:00 AM ET FRAMINGHAM, MA / ACCESSWIRE / March 16, 2023 / Xenetic Biosciences, Inc. (NASDAQ:XBIO) ("Xenetic" or the "Company"), a biopharmaceutical company focused on advancing innovative immune-oncology technologies addressing hard to treat cancers,...

Read more

Celcuity Inc. Schedules Release of Fourth Quarter and Full Year 2022 Financial Results and Webcast/Conference Call

March 16, 2023 8:00 AM

MINNEAPOLIS, MN / ACCESSWIRE / March 16, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced that it will release its financial results for the fourth quarter and full year 2022 after the stock market close on Thursday, March 23, 2023. Management will host a webcast/teleconference the same day at 4:30 p.m. Eastern Time to discuss the results and...

Read more

AmplifyBio Emerges as a Leader in Cell Therapy Characterization, Filling a Gap in Pre-Clinical Development

March 16, 2023 7:00 AM

AmplifyBio builds on the T-cell immunology expertise of its South San Francisco-based team, adding technology platforms and capabilities in single-cell analysis and product assessment in the context of a tumor microenvironment. SAN FRANCISCO, CA / ACCESSWIRE / March 16, 2023 / AmplifyBio, a preclinical CRO provider, spun out from the Battelle corporation in mid-2021, signaled the intention to build on discovery and characterization capabilities...

Read more

Q3 Interim Report November -January 2022/2023

March 16, 2023 3:20 AM

UPPSALA, SWEDEN / ACCESSWIRE / March 16, 2023 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) DiviTum® TKa ready for clinical use in the US SEK t Q3 22/23 Q3 21/22 May-Jan 22/23 May-Jan 21/22 Full year 21/22 Net sales 1,291 314 2,797 963 2,045 Operating profit (loss) -29,277 -14,417 -73,250 -40,970 -60,101 Profit (loss) for the period -28,538 -14,334 -72,793 -40,947 -60,003 Earnings per share, after dilution -0.64 -0.50 -2.33 -1.44...

Read more

Celcuity to Present Preclinical Data on Therapeutic Effects of Gedatolisib in Gynecological Cancer Models at AACR Annual Meeting 2023

March 15, 2023 7:35 PM

MINNEAPOLIS, MN / ACCESSWIRE / March 15, 2023 / Celcuity Inc. (NASDAQ:CELC), a clinical-stage biotechnology company focused on development of targeted therapies for oncology, today announced publication of an abstract reporting data from preclinical studies evaluating gedatolisib and other PI3K/AKT/mTOR inhibitors in endometrial, ovarian, and cervical cancer cell lines. A poster will be presented at the 2023 Annual Meeting of the American...

Read more

Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon Award

March 15, 2023 9:00 AM

Dr. Christopher Wheeler, NovAccess Lead Scientist, Receives Prestigious Golden Axon Award CLEVELAND, OH / ACCESSWIRE / March 15, 2023 / NovAccess Global Inc. (OTCQB:XSNX), a biomedical company developing novel immunotherapies for brain tumor patients, announced that Dr. Christopher Wheeler, Ph.D., President, StemVax Therapeutics Inc., a division of NovAccess Global and the lead scientist for the Company, received the prestigious Golden Axon...

Read more

Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study

March 15, 2023 8:10 AM

28-day survival will be evaluated in ARDS patients hospitalized with Covid-19 Updated protocol approved by study's ethics committee Company exploring pathways for treating general ARDS patients TORONTO, ON / ACCESSWIRE / March 15, 2023 / Edesa Biotech, Inc. (NASDAQ:EDSA), a clinical-stage biopharmaceutical company focused on inflammatory and immune-related diseases, today reported that the company and the U.S. Food and Drug Administration (FDA)...

Read more

Gibson Oncology Expands Its Board of Directors With Accomplished Leadership in Oncology Clinical Development and Corporate Strategy

March 14, 2023 5:55 PM

MIAMI, FL / ACCESSWIRE / March 14, 2023 / Gibson Oncology, a privately held Oncology preclinical and clinical development company advancing novel, targeted small molecule compounds that inhibit topoisomerase I and bind the G4 quadruplex in the cMyc promoter to inhibit cMyc expression as potent anticancer agents, welcomes two well-accomplished and experienced individuals within the life sciences industry, Dr. Fred Mermelstein and Dr. Mark Baganz....

Read more

Lifeloc Reports 2022 Full Year Results

March 14, 2023 9:08 AM

WHEAT RIDGE, CO / ACCESSWIRE / March 14, 2023 / Lifeloc Technologies, Inc. (OTC PINK:LCTC), a global leader in the development and manufacturing of breath alcohol testing devices, has announced financial results for the 2022 fiscal year ended December 31, 2022. 2022 Financial Highlights Lifeloc Technologies posted annual net revenue of $8.482 million resulting in a net loss of $456 thousand in 2022, or ($0.19) per diluted share. These results...

Read more

Nomination Committee for Biovica for the 2023 Annual General Meeting

March 13, 2023 11:15 AM

UPPSALA, SE / ACCESSWIRE / March 13, 2023 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) The Nomination Committee prior to the 2023 Annual General Meeting will consist of three members, who shall represent the two shareholders with the highest number of shares who accept the assignment to be part of the Nomination Committee as of December 31, 2022, and the Chairman of the Board. The Nomination Committee then appoints a chairman...

Read more

Pirche Joins C-Path's Transplant Therapeutics Consortium (TTC)

March 13, 2023 8:00 AM

BERLIN, GERMANY / ACCESSWIRE / March 13, 2023 / The Critical Path Institute (C-Path), an independent nonprofit, public-private partnership with the U.S. Food and Drug Administration (FDA) and Pirche AG, the global leader in AI-powered molecular matching and prediction analysis, announced a new collaboration that will see Pirche become the latest member of C-Path's Transplant Therapeutics Consortium (TTC). "TTC is excited to welcome Pirche to...

Read more